#liver cancer

Results in cell and mouse studies may have implications for the development of a new class of anticancer drugs.

Compared with Asians, other racial and ethnic groups were less likely to receive adequate HBV evaluation and treatment.

People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.

People who are living with all three viruses have a greater likelihood of progressing to end-stage liver disease.

The program aims to expand testing, reduce drug costs and raise awareness of hepatitis C.

Risk-based testing alone has failed to identify a majority of people living with chronic HBV.

Successful antiviral treatment partially turns back the clock on age acceleration.

Researchers suggest cannabis use alone should not be a reason to deny transplants.

Most outcomes were similar in lean and heavy people with fatty liver disease, but the lean group had higher liver-related mortality.

Advocates are working to deliver medication directly to patients to combat this alarming decrease in care.

People treated with direct-acting antivirals had a lower risk for liver failure and liver cancer as well as much lower mortality.

Experts predict that more than a million people could die from liver cancer worldwide in 2040.

Even though as many as 97% of patients can be cured with medication, many still don’t receive the treatment.